緩釋性輔料市場規模、佔有率和成長分析（按類型、技術、給藥途徑和地區分類）－2026-2033年產業預測

預計到 2024 年，緩釋輔料市場規模將達到 17.3 億美元，到 2025 年將達到 18.7 億美元，到 2033 年將達到 34.9 億美元，預測期（2026-2033 年）的複合年成長率為 8.1%。

緩釋性輔料市場是製藥業的重要組成部分，專注於生產緩釋性製劑所需的關鍵輔料。這些製劑能夠促進藥物的持續釋放，進而減少給藥頻率，同時提高患者遵從性和治療效果。在慢性病發病率上升、對創新給藥系統的需求以及緩釋性發展趨勢的推動下，該市場持續擴張。輔料研發的進步，包括新型聚合物和包覆技術的出現，正在為生產商拓展製劑選擇。主要企業正加大研發投入，以提高輔料的性能及其與各種活性藥物成分的相容性。北美和歐洲市場佔據主導地位，而亞太和拉丁美洲市場則因醫療保健服務的改善和製藥技術的進步而呈現強勁成長。在精準醫療和個人化治療的推動下，該市場的未來前景依然樂觀。

緩釋性輔料市場促進因素

人口老化加劇對緩釋輔料市場產生了顯著影響，因為人口結構的變化正在推動對專為老年人設計的醫療保健產品和藥物的需求。這些輔料透過實現藥物的持續釋放發揮關鍵作用，有助於提高患者的用藥依從性，並有效管理慢性疾病。隨著醫療保健機構應對人口老化帶來的獨特挑戰，針對老年患者需求的藥物需求日益成長。預計這種持續的人口結構變化將維持製藥業對緩釋性輔料的強勁需求。

緩釋輔料市場的限制

由於藥品核准和分銷流程受到嚴格監管，緩釋輔料市場面臨許多障礙。這種複雜的法規環境給尋求將新產品推向市場的公司帶來了巨大挑戰。在確保符合現有法規的前提下獲得必要的核准可能是一個漫長而昂貴的過程，而且充滿挑戰。此外，監管標準和指南的頻繁變更可能會擾亂產品開發進度，阻礙市場准入，最終抑制市場成長。這些因素共同導致相關人員難以有效駕馭市場，並可能扼殺產業創新。

緩釋性添加劑市場趨勢

受個人化醫療日益成長的關注，緩釋輔料市場正經歷顯著的發展趨勢。隨著製藥業越來越重視開發針對個別患者需求的藥物，緩釋輔料的創新至關重要。這些輔料能夠實現精準給藥和最佳釋放時間，從而提高療效並減少副作用。這種以患者為中心的醫療保健模式不僅凸顯了客製化給藥系統的重要性，也促進了輔料製劑技術和製程的進步。因此，隨著個人化治療方案的不斷發展，預計該市場將迎來強勁成長。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 監管環境
• 案例研究

全球緩釋性輔料市場規模（按類型和複合年成長率分類）（2026-2033 年）

• 明膠
• 聚合物
• 礦物
• 糖
• 其他

全球緩釋性輔料市場規模（依技術及複合年成長率分類）（2026-2033 年）

• 精準投放
• 微膠囊化
• 伍斯特方法
• 其他

全球緩釋性輔料市場規模（依給藥途徑及複合年成長率分類）（2026-2033 年）

• 口服
• 肌肉內注射
• 皮下注射
• 經皮
• 靜脈注射
• 其他

全球緩釋性輔料市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• International Flavors & Fragrances Inc.（United States）
• Evonik Industries AG（Germany）
• BASF SE（Germany）
• Kerry Group Plc（Ireland）
• Roquette Freres（France）
• Merck KGaA（Germany）
• Associated British Foods Plc（United Kingdom）
• ADM（United States）
• Wacker Chemie AG（Germany）
• Croda International Plc（United Kingdom）
• Gattefosse（France）
• Colorcon Inc.（United States）
• AstraZeneca PLC（United Kingdom）
• GlaxoSmithKline PLC（United Kingdom）
• Mayne Pharma Group Limited（Australia）
• Sun Pharmaceutical Industries Ltd.（India）
• Pfizer Inc.（United States）
• Novartis AG（Switzerland）

結論與建議

Sustained Release Excipients Market size was valued at USD 1.73 Billion in 2024 and is poised to grow from USD 1.87 Billion in 2025 to USD 3.49 Billion by 2033, growing at a CAGR of 8.1% during the forecast period (2026-2033).

The sustained release excipients market represents a critical segment of the pharmaceutical industry, emphasizing the production of excipients essential for sustained release formulations. These formulations facilitate gradual drug release, enhancing patient adherence and therapeutic efficacy while minimizing dosing frequency. The market is expanding, propelled by the rising incidence of chronic diseases, the demand for innovative drug delivery systems, and the trend towards controlled-release formulations. Technological advancements in excipient development, including new polymers and coatings, enhance formulation options for manufacturers. Major players invest in R&D to innovate excipient performance and compatibility with various active pharmaceutical ingredients. Geographically, North America and Europe lead the market, with strong growth emerging in Asia-Pacific and Latin America, fueled by improved healthcare access and pharmaceutical advancements. The future outlook remains bright, driven by a focus on precision medicine and personalized therapies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Sustained Release Excipients market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Sustained Release Excipients Market Segments Analysis

Global Sustained Release Excipients Market is segmented by Type, Technology, Route of Administration and region. Based on Type, the market is segmented into Gelatin, Polymers, Minerals, Sugars and Others. Based on Technology, the market is segmented into Targeted Delivery, Microencapsulation, Wurster Technique and Others. Based on Route of Administration, the market is segmented into Oral, Intramuscular, Subcutaneous, Transdermal, Intravenous and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Sustained Release Excipients Market

The growing elderly population is significantly influencing the sustained release excipients market, as demographic changes lead to an increased need for healthcare products and pharmaceuticals tailored to older individuals. These excipients play a crucial role by allowing extended drug release, which enhances patient compliance and effectively manages chronic health conditions. As healthcare providers respond to the unique challenges presented by an aging demographic, there is a rising demand for medications designed specifically to meet the needs of senior patients. This ongoing shift in demographics is expected to sustain a robust demand for sustained release excipients within the pharmaceutical industry.

Restraints in the Sustained Release Excipients Market

The sustained release excipients market faces significant obstacles due to stringent regulations that oversee drug approval and release processes. This complex regulatory environment presents a major hurdle for companies aiming to bring new products to market. The lengthy and costly process of securing necessary approvals while ensuring compliance with existing regulations can be challenging. Additionally, frequent changes in regulatory standards and guidelines can disrupt product development timelines and hinder market entry, ultimately impeding the growth of the market. This combination of factors makes it difficult for stakeholders to navigate the market effectively and can stifle innovation within the industry.

Market Trends of the Sustained Release Excipients Market

The sustained release excipients market is experiencing a notable trend driven by the increasing focus on personalized medicine. As the pharmaceutical industry places greater emphasis on tailoring medications to individual patient needs, innovations in sustained release excipients have become essential. These excipients allow for precise dosing and optimal release timing, enhancing therapeutic efficacy and reducing side effects. This shift towards patient-centric healthcare not only underscores the importance of customized drug delivery systems but also stimulates advancements in excipient formulations and technologies. As a result, the market is poised for robust growth, aligning with the evolving landscape of personalized therapeutic solutions.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies

Global Sustained Release Excipients Market Size by Type & CAGR (2026-2033)

• Market Overview
• Gelatin
• Polymers
• Minerals
• Sugars
• Others

Global Sustained Release Excipients Market Size by Technology & CAGR (2026-2033)

• Market Overview
• Targeted Delivery
• Microencapsulation
• Wurster Technique
• Others

Global Sustained Release Excipients Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Intramuscular
• Subcutaneous
• Transdermal
• Intravenous
• Others

Global Sustained Release Excipients Market Size & CAGR (2026-2033)

• North America (Type, Technology, Route of Administration)
  • US
  • Canada
• Europe (Type, Technology, Route of Administration)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Technology, Route of Administration)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Technology, Route of Administration)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Technology, Route of Administration)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• International Flavors & Fragrances Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Evonik Industries AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BASF SE (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kerry Group Plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roquette Freres (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Associated British Foods Plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ADM (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Wacker Chemie AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Croda International Plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gattefosse (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Colorcon Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline PLC (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mayne Pharma Group Limited (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations